There are currently 72 active clinical trials seeking participants for Atrial Fibrillation research studies. The states with the highest number of trials for Atrial Fibrillation participants are Florida, California, Ontario and Texas.
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
07/01/2025
Locations: Banner University, Phoenix, Arizona +83 locations
Conditions: Atrial Fibrillation
Register for Updates
Insertable Cardiac Monitor-Guided Early Intervention to Reduce Atrial Fibrillation Burden Following Catheter Ablation
NCT04922281
Recruiting
To prospectively investigate the efficacy of an insertable cardiac monitor-guided atrial fibrillation (AF) management in reducing subsequent AF burden in patients with persistent or paroxysmal AF undergoing atrial catheter ablation (CA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Cardiovascular Diseases, Heart Diseases, Arrhythmias, Cardiac, Pathologic Processes
Register for Updates
Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation
NCT06056271
Recruiting
Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Explorer systems during AF ablation procedures.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/30/2025
Locations: Endeavor Health, Evanston, Illinois +3 locations
Conditions: Atrial Fibrillation
Register for Updates
The CONFORM Pivotal Trial
NCT05147792
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Grandview Medical Center, Birmingham, Alabama +61 locations
Conditions: Atrial Fibrillation, Stroke
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +175 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098
Recruiting
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/20/2025
Locations: Phoenix Cardiovascular Research Group, Phoenix, Arizona +45 locations
Conditions: Atrial Fibrillation
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +71 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Perioperative AF After Noncardiac Surgery
NCT03968393
Recruiting
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient perioperative atrial fibrillation after noncardiac surgery and additional stroke risk factors.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/10/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +104 locations
Conditions: Stroke, Atrial Fibrillation
Register for Updates
Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation
NCT04685317
Recruiting
The purpose of the study is to see if the Sentinel® Cerebral Protection System may prevent occurrence of stroke during an ablation procedure for atrial fibrillation (AF). The secondary purpose of this study is to study if cognitive function after AF ablation differs between those treated with the Sentinel cerebral protection device and those who do not receive the device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Arrhythmia, Atrial Fibrillation
Register for Updates
Mobile Health Technology-Enabled AFib Management
NCT06500988
Recruiting
The overall objective of this proposal is to evaluate the effect on quality of life of a comprehensive digital atrial fibrillation (AFib) management tool that will empower patients to a) take an active role in learning about AFib management options, starting and adhering to evidence-based therapies and lifestyle changes and b) to guide the patients during AFib episodes which are associated with anxiety and impairment in quality of life. Researchers plan to evaluate the effectiveness of this nov... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland +1 locations
Conditions: Atrial Fibrillation, Behavior
Register for Updates
Ondansetron for the Management of Atrial Fibrillation
NCT05844501
Recruiting
"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/27/2025
Locations: Indiana Clinical Research Center, Indianapolis, Indiana +2 locations
Conditions: Atrial Fibrillation
Register for Updates
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Affinity Hospital dba Grandview Medical Center, Birmingham, Alabama +52 locations
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Register for Updates